Skip to content

HELP

Cybin, Inc.

NASDAQ · Healthcare · Biotechnology · CA

$10.69
+1.33%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
-19.9%
EBIT
-19.7%
EPS
+7.2%
Free cash flow
-58.7%
Operating cash flow
-60.2%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
+89.1%
EPS
+56.0%

Three-year CAGR

Revenue
—
EBITDA
+0.8%
EBIT
+1.0%
Net income
-30.0%
EPS
+24.3%
Free cash flow
-29.6%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026